secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0001171843-23-001869
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose reports Q4 net loss $10.0M; cash runway into Q1 2024; tuspetinib expansion trial underway
--------------------------------------------------------------------------------

- Q4 net loss $10.0M ($0.11/sh) vs $24.3M loss year ago; FY2022 net loss $41.8M ($0.45/sh) vs $65.4M.
- Cash and investments $47.0M at Dec 31, 2022; expects funding into Q1 2024.
- APTIVATE Phase 1/2 expansion trial for tuspetinib initiated; monotherapy and TUS/VEN combination arm enrolling.
- Tuspetinib monotherapy showed 29% CR/CRh in RAS-mutated AML patients during dose escalation.
- Luxeptinib G3 formulation shows improved bioavailability; continuous dosing ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184323001869/0001171843-23-001869-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184323001869/f8k_032323.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-001869

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer